Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (EMBC) generates a steady stream of news as a global diabetes care and medical supplies company listed on The Nasdaq Global Select Market. The company describes itself as advancing a 100-year legacy in insulin delivery and working to transform from an insulin delivery company into a broader medical supplies company. News about embecta often reflects this strategic evolution and its role in diabetes care worldwide.
Investors and observers can expect frequent updates tied to financial performance, including quarterly and full-year earnings results. embecta regularly issues press releases detailing revenues by geography and product family, operating margins, adjusted metrics, and guidance for upcoming fiscal years. These announcements are often accompanied by commentary on business drivers such as product volumes, pricing, foreign currency effects, and contract manufacturing activity.
Another key category of news covers strategic initiatives and partnerships. embecta has highlighted its global ERP implementation, brand transition from BD-branded to embecta-branded injection devices, and restructuring efforts aimed at improving profitability and reducing debt. The company also reports on collaborations with pharmaceutical partners to co-package embecta pen needles with potential generic GLP-1 therapies, as well as humanitarian partnerships, including large-scale donations of pen needles and insulin syringes through organizations such as Direct Relief.
embecta’s news flow also includes corporate governance and capital allocation topics, such as board changes, upcoming investor conferences, and regular announcements of quarterly cash dividends. Together, these updates provide insight into how embecta manages its diabetes-focused portfolio, pursues growth opportunities, and communicates with stockholders. For readers tracking EMBC, this news page offers an organized view of the company’s financial disclosures, strategic milestones, and corporate developments over time.
embecta (Nasdaq: EMBC) will report fiscal first quarter 2026 results and host a conference call on Thursday, February 5, 2026 at 8:00 a.m. ET. The call will include an operational update and a Q&A session. Investors can access a live webcast or teleconference, and a webcast replay will be available beginning at 11:00 a.m. ET on February 5, 2026 and archived on the embecta investor relations website for one year.
Embecta (Nasdaq: EMBC) said management will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be available in the News & Events section of the company's investor relations website at investors.embecta.com.
embecta (Nasdaq: EMBC) reported fourth-quarter FY2025 and full-year results for periods ended September 30, 2025.
Key Q4 metrics: revenues $264.0M (down 7.7% YoY), adjusted EBITDA margin 34.1%, GAAP diluted EPS $0.45, adjusted diluted EPS $0.50, and a declared quarterly dividend of $0.15 per share. Full-year results: revenues $1,080.4M (down 3.8% YoY), adjusted EBITDA margin 38.5%, adjusted diluted EPS $2.95, and free cash flow ~$182M.
Operational notes: management cited distributor ordering timing and China dynamics for revenue pressure, completed major separation activities, reduced debt by ~$184.5M in FY2025, and provided preliminary FY2026 guidance: revenues $1,071–$1,093M, adjusted operating margin 29.0%–30.0%, adjusted EPS $2.80–$3.00.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.15 per share.
The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025.
embecta (Nasdaq: EMBC) announced board changes on November 17, 2025. Director David J. Albritton resigned effective immediately for personal reasons, and Non-Executive Chairman LTG (Ret.) David F. Melcher will not stand for re-election and will retire at embecta’s 2026 annual stockholder meeting. Both directors served on the Board since its 2022 inception.
The Board expects to appoint Devdatt “Dev” Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director effective upon Melcher’s departure. The Corporate Governance and Nominating Committee will evaluate desired independent director expertise and recommend potential replacements.
embecta (Nasdaq: EMBC) announced on Nov 14, 2025 a major expansion of its humanitarian partnership with Direct Relief to increase global and U.S. access to diabetes injection devices. Following a North America packaging transition, embecta donated approximately 15 million pen needles and insulin syringes and will continue support through 2026.
The commitment funds emergency response, supports more than 1,600 community health centers serving ~36 million patients, aids the Life for a Child program (53,000+ children in 45 countries), and included a recent 2.7 million unit donation for Sudan; embecta also provided a July 2025 grant of $25,000 for Texas storm relief.
embecta (Nasdaq: EMBC) will report fiscal fourth quarter and full year 2025 results and host a conference call at 8:00 a.m. ET on Tuesday, November 25, 2025. The company says the call will include an operational update and preliminary fiscal year 2026 financial guidance.
Investors can join a live webcast or teleconference via the company’s investor website at investors.embecta.com. A webcast replay will be available beginning at 11:00 a.m. ET on November 25, 2025 and will be archived on the investor site for one year.
Embecta (Nasdaq: EMBC), a medical supplies company specializing in insulin delivery, has announced its participation in two major healthcare investor conferences in September 2025.
At the 2025 Wells Fargo Healthcare Conference on September 4, management will host a fireside chat at 3:00 p.m. EDT and conduct one-on-one investor meetings at the Encore Boston Harbor Hotel. The company will also participate in the 2025 Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, hosting one-on-one investor meetings at the Sheraton New York Times Square.
Embecta (NASDAQ:EMBC) reported strong Q3 fiscal 2025 results with revenues of $295.5 million, up 8.4% year-over-year. The company achieved notable growth in both U.S. (11.6%) and International (5.0%) markets. Key financial metrics include adjusted operating income of $109.1 million with a 36.9% margin, and adjusted earnings per share of $1.12, up from $0.74 in the prior year.
The company completed several strategic initiatives, including implementing their ERP system and operationalizing distribution centers in India. Embecta also made progress in co-packaging agreements for GLP-1 drugs and reduced debt by $52.4 million during Q3, bringing year-to-date debt reduction to $112 million. The company declared a quarterly dividend of $0.15 per share and raised its fiscal 2025 guidance.
Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for its common stock. The dividend will be paid on September 15, 2025, to shareholders of record as of the close of business on August 29, 2025.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
